Terril Brothers Inc. Takes Position in Solventum Co. (NYSE:SOLV)

Terril Brothers Inc. bought a new stake in Solventum Co. (NYSE:SOLV) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 80,856 shares of the company’s stock, valued at approximately $5,341,000. Solventum comprises 1.6% of Terril Brothers Inc.’s investment portfolio, making the stock its 17th largest position.

Other institutional investors and hedge funds have also made changes to their positions in the company. New York Life Investment Management LLC raised its stake in Solventum by 0.7% during the 4th quarter. New York Life Investment Management LLC now owns 18,506 shares of the company’s stock valued at $1,223,000 after acquiring an additional 136 shares during the last quarter. Blue Trust Inc. raised its stake in Solventum by 2.1% during the 4th quarter. Blue Trust Inc. now owns 7,872 shares of the company’s stock valued at $549,000 after acquiring an additional 161 shares during the last quarter. MML Investors Services LLC raised its stake in Solventum by 3.2% during the 3rd quarter. MML Investors Services LLC now owns 5,345 shares of the company’s stock valued at $373,000 after acquiring an additional 168 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. raised its stake in Solventum by 4.2% during the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,966 shares of the company’s stock valued at $346,000 after acquiring an additional 200 shares during the last quarter. Finally, Savant Capital LLC raised its stake in Solventum by 6.3% during the 4th quarter. Savant Capital LLC now owns 3,914 shares of the company’s stock valued at $259,000 after acquiring an additional 233 shares during the last quarter.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Morgan Stanley increased their target price on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. Wells Fargo & Company increased their target price on Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Friday. Mizuho assumed coverage on Solventum in a research note on Wednesday, December 4th. They set a “neutral” rating and a $70.00 target price for the company. Bank of America increased their target price on Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a research note on Wednesday. Finally, Piper Sandler increased their target price on Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a research note on Friday. One research analyst has rated the stock with a sell rating, nine have given a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, Solventum presently has a consensus rating of “Hold” and an average target price of $74.71.

Solventum Stock Performance

SOLV opened at $79.56 on Friday. The stock has a market cap of $13.74 billion and a P/E ratio of 28.93. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The stock’s 50 day simple moving average is $72.51 and its 200 day simple moving average is $69.88. Solventum Co. has a 1-year low of $47.16 and a 1-year high of $96.05.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.